Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2012

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
Revenue of $309 million, a 24% increase compared to $250 million in the fourth quarter of 2011.

Fourth quarter 2012 results:

•    Revenue of $309 million, a 24% increase compared to $250 million in the fourth quarter of 2011
•    GAAP net income for the quarter of $72 million, or $0.53 per diluted share, compared to net income of $12 million, or $0.09 per diluted share, for the fourth quarter of 2011
•    Non-GAAP net income for the quarter of $57 million, or $0.42 per diluted share, compared to $44 million, or $0.35 per diluted share, for the fourth quarter of 2011 (see the table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures)
•    Cash flow from operations of $79 million and free cash flow of $62 million for the quarter

Gross margin in the fourth quarter of 2012 was 65.8% compared to 68.2% in the prior year period. Excluding the effect of non-cash charges associated with stock compensation, amortization of acquired intangibles, and amortization of inventory revaluation costs, non-GAAP gross margin was 68.5% for the fourth quarter of 2012 compared to 70.2% in the prior year period.

Research and development (R&D) expenses for the fourth quarter of 2012 were $56.9 million compared to $45.5 million in the fourth quarter of 2011. R&D expenses included $8.0 million and $7.3 million of non-cash stock compensation expense in the fourth quarters of 2012 and 2011, respectively. Excluding these charges and contingent compensation expense, R&D expenses as a percentage of revenue were 15.4% compared to 15.0% in the prior year period.

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2012 were $79.7 million compared to $60.9 million for the fourth quarter of 2011. SG&A expenses included $14.1 million and $12.7 million of non-cash stock compensation expense in the fourth quarters of 2012 and 2011, respectively. Excluding these charges, contingent compensation, acquired intangible asset amortization, and legal contingencies, SG&A expenses as a percentage of revenue were 19.9% compared to 20.1% in the prior year period.

GAAP net income included the impact of a pre-tax gain of $48.6 million from the sale of the Company's minority ownership interest in deCODE Genetics to Amgen, Inc.

Depreciation and amortization expenses were $18.1 million and capital expenditures were $17.1 million during the fourth quarter of 2012. The Company ended the quarter with $1.35 billion in cash, cash equivalents and short-term investments, compared to $1.19 billion as of January 1, 2012.

Fiscal 2012 results:

•    Revenue of $1.15 billion, a 9% increase over the $1.06 billion reported in fiscal 2011
•    GAAP net income of $151 million, or $1.13 per diluted share, compared to $87 million, or $0.62 per diluted share in fiscal 2011
•    Non-GAAP net income of $210 million, or $1.59 per diluted share, compared to $176 million, or $1.30 per diluted share, in fiscal 2011 (see table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures)

Gross margin for fiscal 2012 was 67.4% compared to 67.2% in fiscal 2011. Excluding the effect of non-cash charges associated with stock compensation, amortization of acquired intangibles, legal contingencies, and amortization of inventory revaluation costs, non-GAAP gross margin was 69.7% for fiscal 2012 compared to 69.0% in fiscal 2011.

R&D expenses for fiscal 2012 were $231.0 million compared to $196.9 million in fiscal 2011. R&D expenses for fiscal 2012 included a one-time impairment charge of $21.4 million related to an in-process research and development asset previously acquired. R&D expenses also included $30.9 million and $32.1 million of non-cash stock compensation expense in fiscal 2012 and 2011, respectively. Excluding these charges and contingent compensation expense, R&D expenses as a percentage of revenue were 15.3% compared to 15.2% in the prior year.

SG&A expenses for fiscal 2012 were $286.0 million compared to $261.8 million in fiscal 2011. SG&A expenses included $55.4 million and $52.3 million of non-cash stock compensation expense in fiscal 2012 and 2011, respectively. Excluding these charges, contingent compensation expense, acquired intangible asset amortization, and legal contingencies, SG&A expenses as a percentage of revenue were 19.5% compared to 19.9% in the prior year.

“We are very pleased with our execution in 2012,” stated Jay Flatley, President and CEO. “We ended the year with a strong performance, and made significant progress on our strategy of growing our clinical business, both organically and through acquisition. We remain optimistic about our growth prospects in 2013 and beyond, in spite of the continuing challenges of the economic environment.”

Highlights since our last earnings release

•    Announced a definitive agreement to acquire Verinata Health, Inc., a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities
•    Completed the acquisition of Moleculo Inc., which will enable the introduction of a novel library prep method and analysis algorithm to produce synthetic read lengths up to 10 Kb
•    Previewed a new, ordered array flow cell technology that will provide a significant increase in cluster density and number of reads per flow cell
•    Announced a new kit for the HiSeq® 2500 which is capable of generating up to 300 Gb in rapid mode
•    Presented an updated MiSeq® roadmap with chemistry and software enhancements to deliver 15 Gb of throughput
•    Announced Nextera® Rapid Capture Exome Kits to provide the fastest exome enrichment workflow on both the HiSeq 2500 and MiSeq
•    Launched TruSeq® DNA PCR-Free Kits, a simple, all-inclusive sample prep solution for whole-genome sequencing
•    Announced TruSeq Targeted RNA Kits for mid-plex gene expression profiling and validation
•    Announced that Caris Life Sciences has selected the MiSeq system to support Caris' evidence-based molecular profiling service
•    Announced that VWR International, LLC, will distribute Illumina's qPCR portfolio within the United States
•    Announced winners of the MiSeq grant program to accelerate original research in microbial ecology, neglected disease, and human health
•    Named Dr. Robert S. Epstein to the Board of Directors
•    Announced a favorable ruling in patent litigation against Complete Genomics, Inc.
•    Announced new grant recipients of our Agricultural Greater Good Initiative at the 21st International Plant and Animal Genome Conference
•    Repurchased $25 million of common stock under our previously announced share repurchase program


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Files Patent Infringement Suit Against Premaitha
Patent infringement suit filed in the United Kingdom against Premaitha Health plc for infringement of NIPT patents.
Monday, March 16, 2015
Science for Life Laboratory Joins the Illumina Genome Network
First European Genome Network partner plans large scale population sequencing program.
Monday, February 24, 2014
Illumina to Provide NGS Technologies to Quest Diagnostics
The multi-year licensing agreement is related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.
Thursday, January 09, 2014
Illumina Names Dr. Robert S. Epstein to its Board of Directors
Dr. Epstein has worked in public health and academia before joining the private sector.
Monday, December 03, 2012
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil
Uncovering mutations found in deadly transmissible cancer could help conservation efforts.
Monday, September 20, 2010
Genomic Medicine Institute Adds Seven Additional Illumina Genome Analyzers
Acquisition expands the capacity of GMI’s recently established Asian Genome Center to 10 Illumina sequencing systems.
Thursday, July 23, 2009
Illumina Announces Personal Genome Sequencing Service
Company has unveiled a service program to provide high-quality personal genome sequencing for consumers.
Friday, June 12, 2009
Illumina Introduces Three new Research Products to Study Genetic Variations Linked to Cancer Development
The expansion will enable profiling of cancer’s unique gene expression and methylation signatures.
Saturday, April 12, 2008
Illumina Sequences the First African Human Genome
Accomplishment marks a significant milestone enabling economical human genome resequencing.
Thursday, February 07, 2008
Illumina Collaborates with Clinical Research Institute to Develop Molecular Diagnostics for Complex Diseases
The agreement recognizes Illumina’s technology and development expertise with Mayo Clinic’s utility to establish new diagnostic technologies.
Wednesday, January 10, 2007
Illumina Genotyping Solutions to Support Study of Inflammatory Bowel Disease
NIDDK1 IBD Genetics Consortium will utilize the Sentrix® HumanHap300 BeadChips and Infinium™ assay reagents.
Saturday, January 14, 2006
Illumina Advances Genetic Analysis of Cancer
Illumina is launching software tools that enable customers to use Infinium™ SNP genotyping data.
Friday, December 16, 2005
Illumina to Conduct Large-Scale Genotyping Study
Study Designed to Understand Genetic Susceptibility, Mechanisms of Disease Progression, and Cancer Therapy Management.
Wednesday, November 09, 2005
Parc Team Purchases Illumina Genotyping Solutions
Illumina to provide Children's Hospital Oakland Research Institute with reagents and instrumentation.
Friday, October 21, 2005
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Combo Tool
Joining molecular components expands ability to manipulate genes in specific cell types.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Genes Associated With Improved Survival for Pancreatic Cancer Patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!